Acute tacrolimus toxicity due to concomitant use of ritonavir (with nirmatrelvir as Paxlovid)

被引：0
|
作者：
Browne, Evan [1 ,4 ]
White, Cameron [2 ]
Darley, David [3 ]
Murnion, Bridin [4 ]
机构：
[1] St Vincents Hosp, Clin Pharmacol & Toxicol Adv Trainee, Sydney, Australia
[2] St Vincents Hosp, Resp Med Adv Trainee, Sydney, Australia
[3] St Vincents Hosp, Sydney, Australia
[4] UNSW Sydney, Fac Med & Hlth, Sch Clin Med, St Vincents Healthcare Clin Campus,Clin Pharmacol, Sydney, Australia
来源：
AUSTRALIAN PRESCRIBER | 2024年 / 47卷 / 06期
关键词：
COVID-19; drug interactions; nirmatrelvir; Paxlovid; ritonavir; tacrolimus;
D O I：
10.18773/austprescr.2024.052
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：192 / 193
页数：2
相关论文
共 50 条
  • [21] Nirmatrelvir+ritonavir/tacrolimus interactionTacrolimus toxicity following off label use and interaction: case report
    Reactions Weekly, 2023, 1954 (1) : 373 - 373
  • [22] Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19
    Buxeraud, Jacques
    Faure, Sebastien
    Fougere, Edouard
    ACTUALITES PHARMACEUTIQUES, 2020, 61 (617): : 10 - 12
  • [23] Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant
    Young, Chelsea
    Papiro, Talia
    Greenberg, Jason H.
    PEDIATRIC NEPHROLOGY, 2023, 38 (04) : 1387 - 1388
  • [24] Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant
    Chelsea Young
    Talia Papiro
    Jason H. Greenberg
    Pediatric Nephrology, 2023, 38 : 1387 - 1388
  • [25] Impact of Nirmatrelvir-Ritonavir on Tacrolimus Concentrations
    Fredrick, S.
    Wise, B.
    Bowman, L.
    DeWolfe, D.
    Taylor, J.
    Melaragno, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 787 - 788
  • [26] Tacrolimus toxicity due to enzyme inhibition from ritonavir
    Snee, Isabel
    Drobina, Joshua
    Mazer-Amirshahi, Maryann
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2023, 69 : 218.e5 - 218.e7
  • [27] Evaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID®) with Concomitant Medications in Real-World Clinical Settings
    Zatovkanukova, Petra
    Vesely, Dalibor
    Sliva, Jiri
    PATHOGENS, 2024, 13 (12):
  • [28] Nirmatrelvir+ritonavir/paracetamol/tacrolimusVarious toxicity and tacrolimus toxicity following drug interactions: case report
    Reactions Weekly, 2023, 1963 (1) : 416 - 416
  • [29] Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
    Hashemian, Seyed Mohammad Reza
    Sheida, Amirhossein
    Taghizadieh, Mohammad
    Memar, Mohammad Yousef
    Hamblin, Michael R.
    Baghi, Hossein Bannazadeh
    Nahand, Javid Sadri
    Asemi, Zatollah
    Mirzaei, Hamed
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 162
  • [30] Safety and Tolerability of Paxlovid (Nirmatrelvir/Ritonavir) in High-risk Patients
    Pesko, Bryan
    Deng, Alexandra
    Chan, Jeannie D.
    Neme, Santiago
    Dhanireddy, Shireesha
    Jain, Rupali
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (11) : 2049 - 2050
12345